0000000000640796

AUTHOR

H Mueller

showing 2 related works from this author

B* production in Z decays

1995

The decay B*→Bγ has been observed with the DELPHI detector at LEP, where the B* meson is produced in Z boson decays. The combination of inclusively reconstructed B mesons with well-measured converted photons yields a measurement of the flavour-averaged B*-B mass difference of 45.5±0.3 (stat.) ±0.8 (syst.) MeV/c2. 95% confidence level upper limits at 6 MeV/c2 are placed on both the isospin (i.e. B+-B0) and the Bs-Bud splitting of the mass difference. The production ratio of B* to B mesons in Z decays is measured to be 0.72±0.03 (stat.) ±0.06 (syst.). Limits on the production cross-section of other hypothetical excited B hadron states decaying radiatively are established. The differential B* …

Particle physicsPhotonPhysics and Astronomy (miscellaneous)MesonElectron–positron annihilationHadronElementary particle01 natural sciencesNuclear physics0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]B meson010306 general physicsNuclear ExperimentEngineering (miscellaneous)BosonDELPHIPhysics010308 nuclear & particles physicsLARGE ELECTRON POSITRON COLLIDERIsospinPARTICLE PHYSICS; LARGE ELECTRON POSITRON COLLIDER; DELPHIPARTICLE PHYSICSFísica nuclearHigh Energy Physics::ExperimentParticle Physics - Experiment
researchProduct

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

2016

BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in t…

Maleasthma ; serious events ; fluticasone ; salmeterol ; AUSTRIExacerbationIntention to Treat AnalysiINHALED CORTICOSTEROIDSSeverity of Illness Indexlaw.invention0302 clinical medicineRandomized controlled triallawimmune system diseasesÚs terapèuticBroncodilatadors030212 general & internal medicineChildFluticasoneRISKACTING BETA-AGONISTS; INHALED CORTICOSTEROIDS; RISK; EXACERBATIONS; METAANALYSIS; MORTALITY; SAFETY; DEATH; FDAMedicine (all)Hazard ratioDEATHGeneral MedicineBronchodilator agentsMiddle AgedFluticasone-Salmeterol Drug CombinationBronchodilator AgentsIntention to Treat AnalysisAnesthesiaSAFETYFemaleSalmeterolFDAmedicine.drugHumanAdultmedicine.medical_specialtyAdolescentSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionate03 medical and health sciencesDouble-Blind MethodInternal medicineAdministration InhalationmedicineHumansMETAANALYSISAsmaBronchodilator AgentAsthmaAgedProportional Hazards ModelsFluticasone-Salmeterol Drug Combinationbusiness.industryMORTALITYACTING BETA-AGONISTSTherapeutic usemedicine.diseaseAsthmarespiratory tract diseasesEXACERBATIONS030228 respiratory systemFluticasone Propionate Salmeterol Xinafoate Drug CombinationProportional Hazards ModelFluticasonebusiness
researchProduct